Abstract: The present invention is directed to novel cyanoalkylamino derivatives that are inhibitors of cysteine protease such as cathepsins K, S, B and L, in particular cathepsin K Pharmaceutical composition comprising these compounds, method of treating diseases mediated by unregulated cysteine protease activity, in particular cathepsin K utilizing these compounds and methods of preparing these compounds are also disclosed.
Type:
Grant
Filed:
November 13, 2002
Date of Patent:
May 13, 2008
Assignee:
Merck Frosst Canada & Co.
Inventors:
Cameron Black, Sheldon N. Crane, Dana Davis, Eduardo L. Setti